@import url(http://finance.paidcontent.org/client/paidcontent/privatelabel.css);
February 10, 2012 at 06:01 AM EST
Changchun BCHT Biotech Acquires Flu Vaccine Technology
Changchun BCHT Biotechnology obtained an exclusive license for a live attenuated influenza (LIAV) vaccine technology from BioDiem, an Australian vaccine company. The license gives BCHT exclusive China rights to the technology for an egg-based production method in pandemic and seasonal influenza vaccines. Although the license is limited to LAIV for private market vaccines, BCHT holds a second license to LAIV for China’s public market in China via a sub-license from the World Health Organization. More details.... Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here